Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
ZacksIntellia’s (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.